US Patent Issued to HANMI PHARM. on Sept. 15 for "Use of trigonal agonist having activities to all of glucagon, GLP-1, and GIP receptors in treatment of sequelae following respiratory infectious diseases" (South Korean Inventors)

ALEXANDRIA, Va., Sept. 15 -- United States Patent no. 12,734,218, issued on Sept. 15, was assigned to HANMI PHARM. Co. LTD. (Hwaseong-si, South Korea).

"Use of trigonal agonist having activities to all of glucagon, GLP-1, and GIP receptors in treatment of sequelae following respiratory infectious diseases" was invented by Jong Suk Lee (Hwaseong-si, South Korea), Jung Kuk Kim (Hwaseong-si, South Korea), Seon Myeong Lee (Hwaseong-si, South Korea), Sang Hyun Lee (Hwaseong-si, South Korea), Jeong A Kim (Hwaseong-si, South Korea), Euh Lim Oh (Hwaseong-si, South Korea) and Chong Yoon Lim (Hwaseong-si, South Korea).

According to the abstract* released by the U.S. Patent & Trademark Office: "Provided is use of a trigonal agonist having activities...